To confirm, that monitoring of BCL11B methylation could be used both as a marker in the diagnostic process and for monitoring minimal residual disease, the validation in a larger cohort with sequential sampling of T-LGLL patients is needed. Here, BCL11B is linked to T-cell large granular lymphocyte leukemia.